Replimune Group Inc
NASDAQ:REPL

Watchlist Manager
Replimune Group Inc Logo
Replimune Group Inc
NASDAQ:REPL
Watchlist
Price: 9.75 USD -6.16% Market Closed
Market Cap: 750.8m USD

Replimune Group Inc
Investor Relations

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

Show more
Loading
REPL
S&P 500
1Y 3Y 5Y 10Y 15Y 20Y

Earnings Calls

No Earnings Calls Available

Management

Mr. Philip Astley-Sparke F.S.A.
Executive Chairman
No Bio Available
Ms. Emily Luisa Hill
Chief Financial Officer
No Bio Available
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
No Bio Available
Dr. Sushil Patel Ph.D.
CEO & Director
No Bio Available
Dr. Robert Coffin Ph.D.
Founder, Chief Scientist & Director
No Bio Available
Mr. Andrew Schwendenman
Chief Accounting Officer & Treasurer
No Bio Available
Mr. Christopher Sarchi
Chief Commercial Officer
No Bio Available
Mr. Paul Bullock
Chief Manufacturing Officer & Framingham Site Head
No Bio Available

Contacts

Address
MASSACHUSETTS
Woburn
500 Unicorn Park Dr
Contacts
+17812229600.0
www.replimune.com
sparklesyt

See Also

Summary
REPL intrinsic value, competitors valuation, and company profile.
DCF Valuation
REPL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REPL stock valuation using valuation multiples.
Wall Street Estimates
REPL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REPL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.